IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (original) A method of treating or inhibiting obesity, metabolic syndrome hypotension, insulin resistance, dyslipoproteinaemia or hyperuricaemia in a mammal, said method comprising administering to said mammal an effective amount of a compound corresponding to formula I,



I

wherein

A^1 is a group of the formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen, or

A^1 and R^2, together with the carbon atoms to which they are bonded, form a C_{5-7}-cycloalkyl group;

Z is a bond, oxygen or carbonyl and

A^2 is C_{1-20}-alkylene.

2. (original) The method of claim 1, wherein R^1 is phenyl-C_{0-4}-alkyl which is substituted in the phenyl ring by lower alkylenedioxy or one to two times by lower alkyl, lower alkoxy, halogen or perfluoro-lower alkyl.

3. (original) The method of claim 1, wherein A^3 is C_{1-20}-alkylene which is substituted one to two times by phenyl, naphthyl, lower alkyl or C_{5-7}-cycloalkyl.

4. (original) The method of claim 1, wherein A^1 and R^2, together with the carbon atoms to which they are bonded, form a C_{5-7}-cycloalkyl group, the sp^3-hybridized carbon atoms of which are replaced one to two times by oxygen.

5. (original) The method of claim 1, wherein A^2 is C_{1-20}-alkylene which is substituted once by C_{1-12}-alkyl, C_{1-12}-alkyl-phenyl or C_{1-12}-alkyloxyphenyl.

6. (original) The method of claim 1, wherein said compound is present in the form of a solvate.

7. (original) The method of claim 1, wherein said compound is present in the form of a hydrate.

8. (original) The method of claim 1, wherein R^2 is hydrogen or halogen.

9. (original) The method of claim 1, wherein the group A^1 is located in the para position relative to the radical -Z-A^2-C(O)-CF_3.

10. (currently amended) A method for inhibiting pancreatic lipase, the method comprising administering to a subject in need thereof a pancreatic lipase inhibiting amount of a compound corresponding to formula **If**



If

wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen;

W is a bond or oxygen;

Y is a bond or oxygen;

Z is a bond, oxygen or carbonyl;

m is a whole number from 0 to 10;

n is a whole number from 0 to 3 and

p is a whole number from 1 to 20.

11. (cancelled)

12. (original) The method of claim 10, wherein R^1 is phenyl-C_{0-4}-alkyl which is substituted in the phenyl ring by lower alkylenedioxy or one to two times by lower alkyl, lower alkoxy, halogen or perfluoro-lower alkyl.

13. (original) A compound selected from the group consisting of:
5-[4-(benzyloxymethyl)-phenoxy]-1,1,1-trifluoropentan-2-one,
5-[4-(benzyloxy)phenoxy]-1,1,1-trifluoropentan-2-one,
1,1,1-trifluoro-12-phenoxy-dodecan-2-one and
1,1,1-trifluoro-5-[4-(3-phenylpropoxy)phenoxy]pentan-2-one.

14. (currently amended) A compound which is ~~selected from the group consisting of:~~
6-(4-methoxyphenyl)-1,1,1-trifluorohexan-2-one ~~and 5-(4-methoxyphenyl)-1,1,1-trifluoropentan-2-one~~.

15. (original) A compound selected from the group consisting of:
1,1,1-trifluoro-9-phenyl-nonan-2-one;

1,1,1-trifluoro-11-phenyl-undecan-2-one and

1,1,1-trifluoro-8-phenyl-octan-2-one.

16. (currently amended) A method of treating or inhibiting obesity, metabolic syndrome hypotension, insulin resistance, dyslipoproteinaemia or hyperuricaemia in a mammal, said method comprising administering to said mammal an effective amount of a compound corresponding to formula **Ig**,



Ig

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen or

A^1 and R^2, together with the carbon atoms to which they are bonded form a

C_{5-7}-cycloalkyl group and

A^2 is C_{1-20}-alkyl.

17. (currently amended) A ~~The~~ compound ~~of claim 16,~~ corresponding to formula Ig,



Ig

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is phenyl-C_{0-4}-alkyl which is substituted in the phenyl ring by lower alkylenedioxy or one to two times by lower alkyl, lower alkoxy, halogen or perfluoro-lower alkyl

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen or

A^1 and R^2, together with the carbon atoms to which they are bonded form a C_{5-7}-cycloalkyl group and

A^2 is C_{1-20}-alkyl.

18. (currently amended) A ~~The~~ compound ~~of claim 16,~~ corresponding to formula **Ig**,



Ig

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene which is substituted one to two times by phenyl, naphthyl, lower alkyl or C_{5-7}-cycloalkyl;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen or

A^1 and R^2, together with the carbon atoms to which they are bonded form a C_{5-7}-cycloalkyl group and

A^2 is C_{1-20}-alkyl.

19. (currently amended) A ~~The~~ compound ~~of claim 16,~~ corresponding to formula **Ig**,



Ig

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen and

A^1 and R^2, together with the carbon atoms to which they are bonded, form a C_{5-7}-cycloalkyl group, the sp^3-hybridized carbon atoms of which are replaced one to two times by oxygen and

A^2 is C_{1-20}-alkyl.

20. (currently amended) A ~~The~~ compound ~~of claim 16,~~ corresponding to

formula Ig,



Ig

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen or

A^1 and R^2, together with the carbon atoms to which they are bonded form a C_{5-7}-cycloalkyl group and

A^2 is C_{1-20}-alkyl which is substituted once by C_{1-12}-alkyl, C_{1-12}-alkyl-phenyl or C_{1-12}-alkyl-oxyphenyl.

21. (currently amended) A ~~The~~ compound ~~of claim 16,~~ corresponding to

formula Ig,



Ig

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen or

A^1 and R^2, together with the carbon atoms to which they are bonded form a C_{5-7}-cycloalkyl group and

A^2 is C_{1-20}-alkyl

wherein said compound is present in the form of a solvate or a hydrate.

22. (cancelled).

23. (currently amended) A ~~The~~ compound ~~of claim 16,~~ corresponding to formula **Ig**,



Ig

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen or

A^1 and R^2, together with the carbon atoms to which they are bonded form a C_{5-7}-cycloalkyl group and

A^2 is ~~stands for~~ substituted n-propylene.

24. (original) A compound according to claim 23, wherein said compound is selected from the group consisting of:

6,6,6-trifluoro-1-(4-methoxyphenyl)hexane-1,5-dione;

6,6,6-trifluoro-1-(4-(4-phenoxybutoxy)phenyl)hexane-1,5-dione;

6,6,6-trifluoro-1-(4-(3-phenylpropoxy)phenyl)hexane-1,5-dione;

1-(4-bromophenyl)-6,6,6-trifluorohexane-1,5-dione;

6,6,6-trifluoro-1-(4-(1-naphthyl)phenyl)hexane-1,5-dione;

6,6,6-trifluoro-1-(5,6,7,8-tetrahydronaphthalen-2-yl)hexane-1,5-dione;

6,6,6-trifluoro-1-(4-(4-methoxy-1-naphthyl)phenyl)hexane-1,5-dione;

6,6,6-trifluoro-1-(4-(2-naphthyl)phenyl)hexane-1,5-dione;

6,6,6-trifluoro-1-(4-(hexadecyloxy)phenyl)hexane-1,5-dione and

6,6,6-trifluoro-1-(4-(tetradecyloxy)phenyl)hexane-1,5-dione.

25. (currently amended) A method of treating or inhibiting obesity, metabolic syndrome hypotension, insulin resistance, dyslipoproteinaemia or hyperuricaemia in a mammal, said method comprising administering to said mammal an effective amount of a compound corresponding to formula **Id**,



Id

wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen;

W is a bond or oxygen;

Y is a bond or oxygen;

m is a whole number from 0 to 10;

n is a whole number from 0 to 3 and

p is a whole number from 1 to 20.

26. (currently amended) A ~~The~~ compound ~~of claim 25,~~ corresponding to formula **Id**,



Id

wherein

R^1 is phenyl-C_{0-4}-alkyl which is substituted in the phenyl ring by lower alkylenedioxy or one to two times by lower alkyl, lower alkoxy, halogen or perfluoro-lower alkyl;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen;

W is a bond or oxygen;

Y is a bond or oxygen;

m is a whole number from 0 to 10;

n is a whole number from 0 to 3 and

p is a whole number from 1 to 20.

27. (original) A compound selected from the group consisting of 1,1,1-trifluoro-7-phenyl-heptan-2-one and 1,1,1-trifluoro-8-phenyl-octan-2-one.

28. (original) A process for the preparation of compounds of corresponding to formula I',



I'

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen, or

A^1 and R^2, together with the carbon atoms to which they are bonded, form a C_{5-7}-cycloalkyl group;

Z' is carbonyl and

A^2 is C_{1-20}-alkylene,

comprising the steps of:

reacting a compound of corresponding to formula **XIb'**



XIb'

with an acetic anhydride compound and

reacting cyclic En-lactones obtained as intermediate products with (trifluoromethyl)trimethylsilane.

29. (original) The process of claim 28, wherein R^1 is phenyl-C_{0-4}-alkyl which is substituted in the phenyl ring by lower alkylenedioxy or one to two times by lower alkyl, lower alkoxy, halogen or perfluoro-lower alkyl.

30. (original) The process of claim 28, wherein A^3 is a bond or C_{1-20}-alkylene which is substituted one to two times by phenyl, naphthyl, C_{1-4}-alkyl or C_{5-7}-cycloalkyl.

31. (original) The process of claim 28, wherein A^1 and R^2, together with the carbon atoms to which they are bonded, form a C_{5-7}-cycloalkyl group, the

sp^3-hybridized carbon atoms of which are replaced one to two times by oxygen.

32. (original) The process of claim 28, wherein A^2 is C_{1-20}-alkylene which is substituted once by C_{1-12}-alkyl, C_{1-12}-alkyl-phenyl or C_{1-12}-alkyl-oxyphenyl.

33. (new) A pharmaceutical composition comprising as an active ingredient a pharmaceutically effective amount of a compound corresponding to formula **Ig**,



Ig

wherein

A^1 is a group corresponding to formula R^1-W-A^3-Y-$(CH_2)_n$-, wherein

R^1 is hydrogen,

lower alkyl,

C_{3-7}-cycloalkyl,

phenyl-C_{0-4}-alkyl or

naphthyl;

W is a bond or oxygen;

A^3 is a bond or C_{1-20}-alkylene;

Y is a bond or oxygen and

n is a whole number from 0 to 3;

R^2 is hydrogen, lower alkyl, lower alkoxy or halogen or

A^1 and R^2, together with the carbon atoms to which they are bonded form a C_{5-7}-cycloalkyl group;

A^2 is C_{1-20}-alkyl and

a pharmaceutically acceptable carrier or adjuvant.